openPR Logo
Press release

Primary Open Angle Glaucoma (POGA) Market to Expand at an Immense Growth Rate During the Forecast Period (2019-32) - Asserts DelveInsight | Key Companies - Laboratorios Sophia, Aerie Pharma, Santen Pharma, MediPrint Ophthalmics, Aerpio Therapeutics, Occul

05-02-2022 12:32 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Primary Open Angle Glaucoma (POGA) Market

Primary Open Angle Glaucoma (POGA) Market

DelveInsight's "Primary Open Angle Glaucoma (POGA) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Primary Open Angle Glaucoma Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Primary Open Angle Glaucoma market report covers emerging drugs, treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Primary Open Angle Glaucoma: An Overview
Glaucoma is a group of conditions in which there is characteristic cupping of the optic disc with corresponding visual field defects, due to retinal ganglion cell loss. It is one of the most common causes of irreversible blindness worldwide. The two major categories of glaucoma are open-angle glaucoma (OAG) and narrow-angle glaucoma. The OAG is primarily divided into two subtypes, i.e., Primary open-angle glaucoma (POAG) and Secondary open-angle glaucoma. It is observed that Primary OAG accounts for 90% of open-angle Glaucoma cases

Primary open-angle glaucoma (POGA) is a syndrome of optic nerve damage associated with an open anterior chamber angle and an elevated or sometimes average intraocular pressure (IOP). POAG is caused by the slow clogging of the drainage canals, resulting in increased IOP. It has a wide and open angle between the iris and cornea.

Primary Open Angle Glaucoma Market Key Facts
As per DelveInsight, in 2020, the total prevalent population of Glaucoma in the US was estimated to be 3,210,300+. In 2020, there were 2,967,468 cases of OAG in the US.
Among the 7MM, the most diagnosed prevalent cases of POAG were recorded in the United States, while the lowest prevalent population of POAG was recorded in Spain.
Among the EU5 countries, Germany has the highest diagnosed prevalent population of POAG, followed by Italy.
The total diagnosed prevalent population of POAG in the US was assessed to be 2,670,700+ in 2020.

Find a sample copy of the Primary Open Angle Glaucoma Market report at:
https://www.delveinsight.com/sample-request/primary-open-angle-glaucoma-poag-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Primary Open Angle Glaucoma Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Primary Open Angle Glaucoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Primary Open Angle Glaucoma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Request a sample and discover more about the report offerings @
https://www.delveinsight.com/report-store/primary-open-angle-glaucoma-poag-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Primary Open Angle Glaucoma Epidemiology
The epidemiology section covers detailed insights into the historical and current Primary Open Angle Glaucoma patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

Explore more about the Primary Open Angle Glaucoma Epidemiology @
https://www.delveinsight.com/report-store/primary-open-angle-glaucoma-poag-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Primary Open Angle Glaucoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Primary Open Angle Glaucoma market or expected to get launched in the market during the study period. The analysis covers Primary Open Angle Glaucoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Report's Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Primary Open Angle Glaucoma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for a sample report to understand more about the Primary Open Angle Glaucoma pipeline development activities @
https://www.delveinsight.com/report-store/primary-open-angle-glaucoma-poag-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Primary Open Angle Glaucoma Therapeutics Assessment
Globally, there are approx. 10+ key companies which are developing the therapies for Primary Open Angle Glaucoma (POAG). The companies which have their Primary Open Angle Glaucoma (POAG) drug candidates in the most advanced stage, i.e. phase III include Laboratorios Sophia S.A de C.V.

Some of the key companies in the Primary Open Angle Glaucoma Therapeutics Market include Laboratorios Sophia S.A de C.V., Aerie Pharmaceuticals, Santen Pharmaceuticals, Chong Kun Dang Pharmaceutical, MediPrint Ophthalmics, Inc., Aerpio Therapeutics, Whitecap Biosciences, LLC, Occular Therapeutics, and Others.

Primary Open Angle Glaucoma Therapies covered in the report include PRO-122, DE-126, and Others.

Learn more about the emerging therapies & key companies in the Primary Open Angle Glaucoma Therapeutics Market @
https://www.delveinsight.com/report-store/primary-open-angle-glaucoma-poag-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Primary Open Angle Glaucoma Report Key Insights
1. Primary Open Angle Glaucoma Patient Population
2. Primary Open Angle Glaucoma Market Size and Trends
3. Key Cross Competition in the Primary Open Angle Glaucoma Market
4. Primary Open Angle Glaucoma Market Dynamics (Key Drivers and Barriers)
5. Primary Open Angle Glaucoma Market Opportunities
6. Primary Open Angle Glaucoma Therapeutic Approaches
7. Primary Open Angle Glaucoma Pipeline Analysis
8. Primary Open Angle Glaucoma Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Primary Open Angle Glaucoma Market

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Primary Open Angle Glaucoma Competitive Intelligence Analysis
4. Primary Open Angle Glaucoma Market Overview at a Glance
5. Primary Open Angle Glaucoma Disease Background and Overview
6. Primary Open Angle Glaucoma Patient Journey
7. Primary Open Angle Glaucoma Epidemiology and Patient Population
8. Primary Open Angle Glaucoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Primary Open Angle Glaucoma Unmet Needs
10. Key Endpoints of Primary Open Angle Glaucoma Treatment
11. Primary Open Angle Glaucoma Marketed Products
12. Primary Open Angle Glaucoma Emerging Therapies
13. Primary Open Angle Glaucoma Seven Major Market Analysis
14. Attribute Analysis
15. Primary Open Angle Glaucoma Market Outlook (7 major markets)
16. Primary Open Angle Glaucoma Access and Reimbursement Overview
17. KOL Views on the Primary Open Angle Glaucoma Market.
18. Primary Open Angle Glaucoma Market Drivers
19. Primary Open Angle Glaucoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Primary Open Angle Glaucoma Market report here:
https://www.delveinsight.com/sample-request/primary-open-angle-glaucoma-poag-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Open Angle Glaucoma (POGA) Market to Expand at an Immense Growth Rate During the Forecast Period (2019-32) - Asserts DelveInsight | Key Companies - Laboratorios Sophia, Aerie Pharma, Santen Pharma, MediPrint Ophthalmics, Aerpio Therapeutics, Occul here

News-ID: 2615554 • Views:

More Releases from DelveInsight Business Research

DelveInsight Unveils Comprehensive Epidemiology Assessment of Cutaneous Squamous Cell Carcinoma (cSCC) Across 15 Countries
DelveInsight Unveils Comprehensive Epidemiology Assessment of Cutaneous Squamous …
DelveInsight, a global leader in healthcare research and analytics, announces the release of its in-depth Cutaneous Squamous Cell Carcinoma (cSCC) Epidemiology Assessment, providing unparalleled insights into the prevalence of cSCC among solid organ transplant recipients across 15 countries, including the United States, key European nations, and select countries in the Asia-Pacific (APAC) region. The newly released assessment delivers country-specific epidemiological insights aimed at guiding strategic decision-making for pharmaceutical companies, healthcare providers,
Unlocking Market Potential: DelveInsight's Comprehensive Patent Foramen Ovale (PFO) Device Landscape Analysis Empowers Strategic Market Entry in the EU
Unlocking Market Potential: DelveInsight's Comprehensive Patent Foramen Ovale (P …
DelveInsight's Market Size & Forecast Assessment Provides Data-Driven Insights for Patient-Centric Market Expansion Strategies DelveInsight, a leading healthcare market research and consulting firm, has released an in-depth case study highlighting its latest assessment of the Patent Foramen Ovale (PFO) Device Market across the European Union. This strategic market intelligence report provides a holistic understanding of the patient population, device market size, competitor landscape, and reimbursement scenario, equipping medical device companies with
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market Poised for Robust Growth at 6.35% CAGR through 2032, States DelveInsight
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market Poised for …
The Chronic Obstructive Pulmonary Disease (COPD) Treatment Devices Market is set for strong expansion, projected to grow at a CAGR of 6.35% from 2025 to 2032, according to recent industry findings. This growth is primarily fueled by the increasing global prevalence of COPD, escalating exposure to tobacco smoke and air pollution, expanding screening programs, and the rapid development of next-generation respiratory devices such as portable nebulizers and smart inhalers. The global
CD40 Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight
CD40 Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, CD40 pipeline constitutes key companies continuously working towards developing CD40 treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "CD40 Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CD40 Market. The CD40 Pipeline report embraces in-depth commercial and

All 5 Releases


More Releases for Primary

Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships. Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy Email primaryhealthcare@pulsusgathering.org On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5% Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk